---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-154190"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:23:24.738281+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Agios director John Maraganore resigns; Catherine Owen elected to board

## Summary
- John Maraganore resigned from board effective May 24, 2023, after nearly 12 years.
- Kaye Foster appointed lead independent director; Cynthia Smith becomes Compensation & People Committee chair.
- Catherine Owen elected as class II director effective June 13, 2023; joins Compensation & People Committee.
- Owen receives annual cash: $50,000 as director plus $7,500 for committee service.
- Owen granted initial equity: nonstatutory option with $472,500 Black-Scholes value and RSUs valued at $157,500.

## SEC filing metadata
- accession: 0001193125-23-154190
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/d509829d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-154190
- JSON: https://secwatch.observer/filing/0001193125-23-154190.json
- Plain text: https://secwatch.observer/filing/0001193125-23-154190.txt

## Key facts
- Executive change
  John Maraganore resigned as Director at AGIOS PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director
  source text: John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm
- Executive change
  Catherine Owen was elected as Director at AGIOS PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Director
  source text: elected Catherine Owen as a director, effective as of June 13, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm
- Executive change
  Kaye Foster was appointed as Lead Independent Director at AGIOS PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Lead Independent Director
  source text: appointed director Kaye Foster to serve as the Board’s lead independent director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.